The Limited Times

Now you can see non-English news...

New crown pneumonia

2020-07-18T04:21:25.629Z


Remdesivir, a drug considered to be effective in the treatment of new coronavirus pneumonia, has been clinically tested on some patients diagnosed in Hong Kong. The Pharmacy and Poisons Board met today (17th) and agreed to conditional approval The redcive drug produced by Gilead Sciences is registered in Hong Kong for the treatment of new coronary pneumonia. The committee said that even though the safety and efficacy data of the drug are still limited, considering that there are no other drugs registered for the treatment of new coronary pneumonia, it is conditionally approved to register in Hong Kong, but Gilead still has to comply with the requirements of the committee To submit further clinical studies and post-marketing reports.


Social News

Written by: Chen Qianting

2020-07-17 23:29

Date of last update: 2020-07-18 01:03

Remdesivir, a drug considered to be effective in the treatment of new coronavirus pneumonia, has been clinically tested on some patients diagnosed in Hong Kong. The Pharmacy and Poisons Board met today (17th) and agreed to conditional approval The redcive drug produced by Gilead Sciences is registered in Hong Kong for the treatment of new coronary pneumonia.

The committee said that even though the safety and efficacy data of the drug are still limited, considering that there are no other drugs registered for the treatment of new coronary pneumonia, it is conditionally approved to register in Hong Kong, but Gilead still has to comply with the requirements of the committee To submit further clinical studies and post-marketing reports.

The Pharmacy and Poisons Committee of the Hong Kong Pharmacy and Poisons Board has conditionally approved the drug registration of Veklury (containing active ingredient ridxivir) today. The holder of the registration certificate is Gilead Sciences Hong Kong Limited (Gilead Sciences) . The Drug Office of the Department of Health is responsible for providing professional and administrative support to the bureau and committees.

In order to expedite the registration and approval of drugs for new coronavirus pneumonia, the committee held a temporary meeting to evaluate the relevant applications. Although there are only very limited data on safety, efficacy and quality, the committee considers the current public health emergencies related to new coronary pneumonia, local medical needs, and that there are currently no other drugs registered for the treatment of new pneumonia. Desivir is still more effective than risk in the treatment of new coronary pneumonia, and decided to make conditional approval for the application for registration of related drugs.

Under conditional approval registration, Gilead Science still needs to submit further clinical research and safety, efficacy and quality data to the Drug Office of the Department of Health according to the conditions imposed by the committee.

HA: Pay close attention to the latest registration of drugs

Earlier, more than 30 patients in Princess Margaret Hospital, Prince of Wales Hospital and Mary Hospital participated in the clinical test of the new drug Remdesivir. A HA spokesman said that the test of the relevant patient has been completed earlier, and it is not yet available. There are other clinical trials of ridxivir which will closely monitor the latest status of the drug registration in Hong Kong.

New Coronary Pneumonia|Two Shatian firefighters had to be quarantined after playing with the diagnosed

New Crown Pneumonia|Niuchiwan Market Closes Clean Neighborhood: Washing Too Late

New Crown Pneumonia|Brother Mei Yanfang City Garden Epidemic Building Opens Food Store Renovation Memorial Hall

New Coronary Pneumonia | City Garden Female Patient Diagnosed After Cardiac Arrest

New Coronary Pneumonia | At least 13 more locally diagnosed cases are related to Ciyun Mountain

Neocoronal pneumonia

Source: hk1

All news articles on 2020-07-18

You may like

Life/Entertain 2024-03-27T03:14:28.641Z
Life/Entertain 2024-03-27T06:06:38.695Z

Trends 24h

News/Politics 2024-03-28T06:04:53.137Z
News/Politics 2024-03-28T05:25:00.011Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.